Table 1 Baseline clinical characteristics
Patient-level characteristics | Sirolimus- and probucol-eluting stent (n = 575) | Zotarolimus-eluting stent (n = 295) | P value |
|---|---|---|---|
Age (years) | 69 (61–76) | 70 (62–76) | 0.40 |
Female | 150 (26.1) | 79 (26.8) | 0.83 |
Diabetes mellitus therapy | |||
Insulin | 197 (34.0) | 109 (37.0) | 0.43 |
Oral antidiabetic drugs | 289 (50.0) | 149 (51.0) | 0.94 |
Hypertension | 547 (95.1) | 281 (95.3) | 0.94 |
Hypercholesterolemia | 389 (68.0) | 188 (64.0) | 0.25 |
Current smoker | 105 (18.0) | 52 (18.0) | 0.82 |
Prior myocardial infarction | 177 (30.8) | 85 (28.8) | 0.55 |
Prior bypass surgery | 59 (10.3) | 34 (11.5) | 0.57 |
Clinical presentation | 0.46 | ||
Silent ischemia | 36 (6.3) | 15 (5.1) | Â |
Stable angina | 324 (56.3) | 154 (52.2) | Â |
Unstable angina | 98 (17.0) | 61 (20.7) | Â |
Non ST-segment elevation myocardial infarction | 73 (12.7) | 45 (15.3) | Â |
ST-segment elevation myocardial infarction | 44 (7.7Â %) | 20 (6.8Â %) | Â |
Multi-vessel disease | 517 (89.9) | 263 (89.2) | 0.73 |
Ejection fraction (%)a | 54 (44-60) | 55 (41–61) | 0.56 |
Lesion-level characteristics | Sirolimus- and probucol-eluting stent (n = 849) | Zotarolimus-eluting stent (n = 439) | P value |
|---|---|---|---|
Target vessel | 0.11 | ||
Left anterior descending | 336 (39.6) | 196 (44.6) | Â |
Left circumflex | 236 (27.8) | 123 (28.0) | |
Right coronary artery | 277 (32.6) | 120 (27.3) | |
Chronic total occlusion | 56 (6.6) | 22 (5.0) | 0.26 |
Bifurcation | 200 (23.6) | 112 (25.5) | 0.44 |
Ostial | 152 (17.9) | 80 (18.2) | 0.89 |
Complex morphology | 626 (74.0) | 336 (77.0) | 0.27 |
Lesion length (mm) | 16.6 ± 9.5 | 17.9 ± 10.4 | 0.07 |
Reference vessel diameter (mm) | 2.75 ± 0.52 | 2.79 ± 0.51 | 0.36 |
Minimal luminal diameter (mm) | 0.91 ± 0.50 | 0.92 ± 0.47 | 0.83 |
Percent diameter stenosis (%) | 67 ± 16 | 67 ± 15 | 0.83 |